Allogeneic non-myeloablative stem cell transplantation utilizing matched family member stem cells purged using Campath-1H [alemtuzumab].

Trial Profile

Allogeneic non-myeloablative stem cell transplantation utilizing matched family member stem cells purged using Campath-1H [alemtuzumab].

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Bone marrow disorders; Graft-versus-host disease; Haematological malignancies; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Planned End Date changed from 1 May 2012 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 27 Feb 2008 Status change from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top